Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Summit Therapeutics Inc SMMT

Healthcare Biotechnology
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SMMT)

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 23 hours ago

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Business Wire October 30, 2024

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Business Wire October 23, 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 4, 2024

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Business Wire October 3, 2024

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Business Wire September 16, 2024

Summit Therapeutics Raises $235 Million

Business Wire September 12, 2024

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

Business Wire September 8, 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 6, 2024
View More News ››

Opinion & Analysis (NDAQ:SMMT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SMMT)

Summit Therapeutics Inc. (NASDAQ: SMMT) Sets New 52-Week Hig

Breaking News: $SMMT Summit Therapeutics Inc. (NASDAQ: SMMT) Sets New 52-Week High in Wednesday SessionShares of Summit Therapeutics Inc...
whytestocks - September 11, 2024

BUY BUY BUY BUY BUY

Halted at 19:30 friday after market  Hoping for merck to buy them at 75$ /SHARE
Nibinator - June 2, 2024

BUY BUY BUY BUY BUY

I see rainbows in the sky 
Nibinator - June 1, 2024

Summit Therapeutics to Present at the Barclays 26th Annual G

BREAKING NEWS: $SMMT Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceSummit Therapeutics Inc...
whytestocks - March 5, 2024

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Ge

News; $SMMT Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek...
whytestocks - February 21, 2024

Summit Therapeutics Announces Updated Phase II Data for Ivon

Just In: $SMMT Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare ConferencePhase...
whytestocks - January 8, 2024
View more Bullboard ››

Cascadia Minerals Ltd

Cascadia Minerals Ltd

Cascadia is a Canadian junior mining company focused on exploring for copper and gold in the Yukon and British Columbia ...
View More »